This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Petrowsky, H.
Right arrow Articles by Fong, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Petrowsky, H.
Right arrow Articles by Fong, Y.

 Previous Article  |  Next Article 

Journal of Virology, August 2001, p. 7050-7058, Vol. 75, No. 15
0022-538X/01/$04.00+0   DOI: 10.1128/JVI.75.15.7050-7058.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Functional Interaction between Fluorodeoxyuridine-Induced Cellular Alterations and Replication of a Ribonucleotide Reductase-Negative Herpes Simplex Virus

Henrik Petrowsky,1 Gretchen D. Roberts,1 David A. Kooby,1 Bryan M. Burt,1 Joseph J. Bennett,1 Keith A. Delman,1 Stephen F. Stanziale,1 Thomas M. Delohery,2 William P. Tong,3 Howard J. Federoff,4 and Yuman Fong1,*

Rockefeller Research Laboratories, Department of Surgery,1 Flow Cytometry Core Facility,2 and Program of Molecular Pharmacology and Therapeutics,3 Memorial Sloan-Kettering Cancer Center, New York, New York 10021, and The Center for Aging and Developmental Biology, Aab Institute of Biomedical Science, University of Rochester Medical Center, Rochester, New York 146424

Received 17 January 2001/Accepted 16 April 2001

G207 is an oncolytic herpes simplex virus (HSV) which is attenuated by inactivation of viral ribonucleotide reductase (RR) and deletion of both gamma 134.5 genes. The cellular counterparts that can functionally substitute for viral RR and the carboxyl-terminal domain of ICP34.5 are cellular RR and the corresponding homologous domain of the growth arrest and DNA damage protein 34 (GADD34), respectively. Because the thymidylate synthetase (TS) inhibitor fluorodeoxyuridine (FUdR) can alter expression of cellular RR and GADD34, we examined the effect of FUdR on G207 bioactivity with the hypothesis that FUdR-induced cellular changes will alter viral proliferation and cytotoxicity. Replication of wild-type HSV-1 was impaired in the presence of 10 nM FUdR, whereas G207 demonstrated increased replication under the same conditions. Combined use of FUdR and G207 resulted in synergistic cytotoxicity. FUdR exposure caused elevation of RR activity at 10 and 100 nM, whereas GADD34 was induced only at 100 nM. The effect of enhanced viral replication by FUdR was suppressed by hydroxyurea, a known inhibitor of RR. These results demonstrate that the growth advantage of G207 in FUdR-treated cells is primarily based on an RR-dependent mechanism. Although our findings show that TS inhibition impairs viral replication, the FUdR-induced RR elevation may overcome this disadvantage, resulting in enhanced replication of G207. These data provide the cellular basis for the combined use of RR-negative HSV mutants and TS inhibitors in the treatment of cancer.


* Corresponding author. Mailing address: Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021. Phone: (212) 639-2016. Fax: (212) 639-4031. E-mail: fongy{at}mskcc.org.


Journal of Virology, August 2001, p. 7050-7058, Vol. 75, No. 15
0022-538X/01/$04.00+0   DOI: 10.1128/JVI.75.15.7050-7058.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Pandha, H. S., Heinemann, L., Simpson, G. R., Melcher, A., Prestwich, R., Errington, F., Coffey, M., Harrington, K. J., Morgan, R. (2009). Synergistic Effects of Oncolytic Reovirus and Cisplatin Chemotherapy in Murine Malignant Melanoma. Clin. Cancer Res. 15: 6158-6166 [Abstract] [Full Text]  
  • Yu, Y. A., Galanis, C., Woo, Y., Chen, N., Zhang, Q., Fong, Y., Szalay, A. A. (2009). Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68. Molecular Cancer Therapeutics 8: 141-151 [Abstract] [Full Text]  
  • Lin, S.-F., Gao, S. P., Price, D. L., Li, S., Chou, T.-C., Singh, P., Huang, Y.-Y., Fong, Y., Wong, R. J. (2008). Synergy of a Herpes Oncolytic Virus and Paclitaxel for Anaplastic Thyroid Cancer. Clin. Cancer Res. 14: 1519-1528 [Abstract] [Full Text]  
  • Aghi, M., Rabkin, S., Martuza, R. L. (2006). Effect of Chemotherapy-Induced DNA Repair on Oncolytic Herpes Simplex Viral Replication. JNCI J Natl Cancer Inst 98: 38-50 [Abstract] [Full Text]  
  • Stanziale, S. F., Petrowsky, H., Adusumilli, P. S., Ben-Porat, L., Gonen, M., Fong, Y. (2004). Infection with Oncolytic Herpes Simplex Virus-1 Induces Apoptosis in Neighboring Human Cancer Cells: A Potential Target to Increase Anticancer Activity. Clin. Cancer Res. 10: 3225-3232 [Abstract] [Full Text]  
  • Cinatl, J. Jr., Cinatl, J., Michaelis, M., Kabickova, H., Kotchetkov, R., Vogel, J.-U., Doerr, H. W., Klingebiel, T., Driever, P. H. (2003). Potent Oncolytic Activity of Multimutated Herpes Simplex Virus G207 in Combination with Vincristine against Human Rhabdomyosarcoma. Cancer Res. 63: 1508-1514 [Abstract] [Full Text]